multiple neuritis

(redirected from polyneuropathy)
Also found in: Dictionary, Thesaurus, Medical, Financial, Wikipedia.

multiple neuritis

[′məl·tə·pəl nu̇′rīd·əs]
(medicine)
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
Mentioned in ?
References in periodicals archive ?
Food and Drug Administration (FDA) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Research By Treatment (Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis (Plasma Exchange), Physiotherapy, Others), Diagnosis (Electrodiagnostic Testing, Nerve Conduction, EMG, Spinal Fluid Analysis, Others), By Route of Administration (Intravenous, Oral, Others), By End User (Hospitals, Specialty Neurological Clinics, Research & Academic Laboratories, Others) and Top Regions Forecast till 2023.
All patients with the diagnosis of acute inflammatory polyneuropathy were included in the study.
Cardiac complications were most frequently observed in 09(16%) patients while polyneuropathy was the other major complication observed in 2(3.57%) patients.
The patient was discharged 8 days later with a diagnosis of acute demyelinating polyneuropathy with sensory predominance and probable Guillain-Barre syndrome due to areflexia, hyperproteinorrhachia, and the clinical picture of the infection that occurred 3 weeks earlier.
The company said ONPATTRO is the first-of-its kind RNA interference (RNAi) therapeutic approved by the US Food and Drug Administration (FDA) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
David Adams, M.D., Ph.D., from the Université Paris-Sud, and colleagues conducted a phase 3 trial involving patients with hereditary transthyretin amyloidosis with polyneuropathy receiving either patisiran (148 patients) or placebo (77 patients).
Material and Methods: In this study, one hundred and sixty five diagnosed patients of diabetic polyneuropathy presenting to medical OPD with complaints of paresthesia/numbness/pain in hands were recruited.
Foot deformities, muscle atrophy, weakness or absence of reflexes are suggestive of a hereditary polyneuropathy, but negative family history and nerve conduction studies guided us to exclude this diagnosis in our patient.
Macro- and micronutritional deficiencies may occur in some patients after bariatric surgery and can result in serious neurological sequelae, [5] including polyneuropathy. Contributing factors comprise drugs, metabolic disorders, environmental exposure, vitamin deficiencies, conversion disorders, and inflammation.
Tafamidis, an oral, non-NSAID, highly specific TTR stabilizer has emerged as the new standard of care for ATTRV30M and remains the only medicine approved for the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy [7].
The other nerve conduction studies (median, ulnar, tibial, and sural) were within normal limits and polyneuropathy was ruled out.